Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers

Metastatic Cancer Clinical Trial

Official title:

Phase II Basket Trial to Evaluate Safety and Efficacy of Neratinib, An Irreversible Tyrosine Kinases Inhibitor of EGFR, ERBB2 and ERBB4 Receptors and Trastuzumab Biosimilar (Herzuma®) in Patients With HER2 Mutated Advanced Solid Cancers

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06083662
• Other study ID #: AL20-17
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 15, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: March 2024
• Source: Korea University Guro Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial

Study drug : neratinib + herzuma (trastuzumab biosimilar)

Description:

1. Primary objective Evaluate overall response rate (ORR) in HER2 mutated advanced solid cancer patients based on RECIST v1.1

2. Secondary objectives

(1) Evaluate clinical benefit rate (CBR) (2) Evaluate duration of response (DOR) (3) Evaluate progression free survival (PFS) (4) Evaluate overall survival (OS) (5) Evaluate compliance with oral administration 3) Safety evaluation

1. Evaluate the overall safety of the test drug

2. Evaluate the predefined adverse event (diarrhea)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 42
• Est. completion date: June 30, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Patients who voluntarily decide to participate and give written consent after hearing the explanation of the clinical trial and investigational drugs.

• Adult men and women over 19 years old.

• Histological or cytological confirmed advanced solid tumor and confirmed to have HER2 known oncogenic mutations in tumor DNA by K-master panel test using tumor tissues or circulating tumor DNA in blood.

• Patients having at least 1 or more than 1 measurable lesion according to RECIST v 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status 0~2.

• Patients whose life expectancy is more than 6 months.

• Metastatic/progressive solid cancer patients who have received one or more than one standard treatment or do not have any treatment option.

• Patients who have agreed to provide plasma/blood samples, the most recent metastatic/progressive tumor sample or new tumor biopsy for gene sequencing and other biomarker analysis.

Exclusion Criteria:

• Patients who received radiotherapy or surgical treatment within 2 weeks prior to the initiation of investigational product.

• Patients having symptomatic brain metastasis who needs treatment. Patients with stable brain metastasis who need no treatment including steroid are eligible

• Inappropriate HER2 mutation (e.g., non-Hot Spot mutation, variant of unknown siginificance, subclonal mutation, premature STOP codon or the Frame Shift mutation).

• Patients having difficulties in swallowing tablets.

• Patients with toxicities of prior treatment which are not recovered to baseline level or = Grade 1.

• Inadequate organ functions:

1. Hemoglobin (Hemoglobin) < 8 .0g / dL

2. Absolute neutrophil count (ANC) < 1. 0 x10 ³ per mm³

3. Platelet count < 100 x10?/L (100 ,000/ mm³)

4. Total bilirubin > 1.5 x upper normal limits (UNL), (exclude Gilbert's syndrome)

5. Alanine aminotransferase (ALT) or aspartate amino transferase (AST) > 3 x upper normal limits (UNL) (in case of liver and bone metastases > 5 x ULN)

6. Serum creatinine >1.5 x upper normal limits (UNL) or < eGFR 30 mL/min/1.73 m² 7) Left ventricle ejection fraction <50% by multi-gate obtaining method scan (MUGA) or echocardiogram.

8) Chronic gastrointestinal disorders of which a main symptom is diarrhea (e.g., Crohn's disease, malabsorption, or grade 2 or more than grade 2 diarrhea according to the NCI CTCAE version 5.0 regardless of etiology).

Related Conditions & MeSH terms

• HER2 Gene Mutation
• Metastatic Cancer
• Neoplasm Metastasis

Intervention

Drug:
• Neratinib Maleate
neratinib 240mg po daily herzuma 8mg/kg (loading) --> 6mg/kg q3w

Locations

Country	Name	City	State
Korea, Republic of	Korea university Guro hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Korea University Guro Hospital	Korean Cancer Study Group

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall response rate (ORR)	ORR according to RECIST v1.1	at 6 months
Secondary	clinical benefit rate, CBR	CR+PR + SD more than 12 weeks	at 6 months
Secondary	median duration of response, DOR	DOR is related to the quality of life and is one of the methods for evaluating tumor response approved by pharmaceutical regulatory agencies	at 6 months
Secondary	median progression free survival, PFS	from enrollment to disease progression, death or withdrawal	at 6 months
Secondary	safety profiles	safety profiles according to CTCAE 4.0	at 6 months